Last reviewed · How we verify
Intralipid 10%
At a glance
| Generic name | Intralipid 10% |
|---|---|
| Also known as | Intralipid |
| Sponsor | University Hospital, Geneva |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- Role of Intralipid in Management of Organophosphorus Poisoning (PHASE2, PHASE3)
- A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses (PHASE2)
- A-TANGO Phase 2 Study (PHASE2)
- Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities (PHASE1)
- Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis (PHASE2)
- Lipid Challenge in Adults (NA)
- Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intralipid 10% CI brief — competitive landscape report
- Intralipid 10% updates RSS · CI watch RSS
- University Hospital, Geneva portfolio CI